Hims & Hers Stumbles as GLP-1 Compounding Ends. Lilly Presses the Advantage.
Eli Lilly releases cheaper vials of the weight-loss drug for self-paying patients and cuts the price of two existing doses.
ENDPOINTS NEWS46m
Hims eyes growth in its weight loss busi­ness, de­spite end of semaglu­tide short­age
Hims & Hers expects revenue from its weight loss business to soar in 2025, even though a recent FDA move could make it ...
What is metformin, the old diabetes drug some people are taking for weight loss?
The telehealth company Hims & Hers has made waves for its Super Bowl ad that plugged its lower-priced form of injectable ...
Novo Nordisk Stock Rises on Weight-Loss Retreat by Hims & Hers
Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...
WXYZ1h
Hims and Hers likely to stop selling cheaper versions of GLP-1 medications
The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...
Hims & Hers Health, Inc. (NYSE:HIMS) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 24, 2025 Hims & Hers Health, Inc. beats earnings expectations. Reported EPS is $0.11, expectations were $0.09. Operator: Good afternoon, ladies and gentlemen, ...
devdiscourse2h
Healthcare Dynamics: Challenges and Innovations Amid Global Shifts
A series of important developments in the healthcare sector includes Medtronic adapting to tariff threats, Hims & Hers facing ...
Novo Nordisk’s stock is rallying as Hims & Hers’ stock falters. An Ozempic alternative won’t be available for long.
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...
There are dot-com echoes beyond tech. This Costco shareholder explains why returns will be paltry at best.
Ahead of whatever Jensen Huang & Co. announces, let's look at another highflying stock: Costco Wholesale (COST). Christopher Bloomstran, the president and chief investment officer St. Louis-based ...
Hims & Hers Health Shares Tumble as its Weight-Loss Treatments Face Tough Environment
Hims is pivoting after drugmaker Novo Nordisk on Friday said the Food and Drug Administration has determined that the shortage of Wegovy and Ozempic has been resolved. Compounding its challenges in ...
Hims & Hers shares drop on doubts over weight-loss business forecast
Shares of Hims & Hers Health tumbled 18% premarket on Tuesday as Wall Street analysts questioned the telehealth provider's lofty sales forecast in the face of looming restrictions on compounded weight ...